Therapy
Secukinumab
Monoclonal antibody targeting IL-17A.
Also called: secukinumab, Cosentyx, SEC
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 3 and is affected by 2 concepts — mostly 1 molecule, 1 disease, 1 pathogen.
- 3Where it sits: therapy on the 15-step immune chain.
What it does
Fully human IgG1κ (no enhanced ADCC vs ixekizumab IgG4κ); anti-IL-17A; approved: psoriasis, PsA, AS, NR-axSpA; Contraindication: active IBD (IL-17A maintains gut barrier); Candida mucosal infections; ERASURE/FIXTURE Phase 3 (plaque psoriasis); first anti-IL-17A class drug
Its connections at a glance
Each dot is a concept directly linked to Secukinumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I004 · concept status: established. Select any connection above to inspect evidence for that specific link.